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Abstract
Background:  Congestive heart failure (CHF) is associated with cognitive deficits, particularly of
memory and attention. The present study aims to clarify whether clinical treatment can reverse the
attentional deficits of patients with CHF.
Methods:  A convenience sample of 50 patients with CHF functional class IV and 30 elderly
controls were recruited from a teaching hospital in Brazil. Participants received a clinical and
cognitive examination that included the Mini-Mental State Examination (MMSE), Cambridge
Cognitive Examination of the Elderly (CAMCOG), Digit Span, Digit-Symbol Substitution, and Letter
Cancellation test. The cognitive performance of CHF patients was reassessed 6 weeks after the
introduction of clinical treatment.
Results:  Twenty-seven CHF subjects had MMSE<24, compared to only 10 of the controls (p =
0.07). CHF patients also had lower CAMCOG scores (mean = 71.8) than controls (mean = 82.0;
p < 0.01). Digit Span, Digit Symbol and Letter Cancellation scores were lower for patients with
CHF than controls (p < 0.01). Similarly patients with CHF took longer to complete the Trail Making
A (p = 0.07) and B (p < 0.01). CAMCOG scores and left ventricular ejection fraction were
moderately correlated (rho = 0.4, p < 0.01). Nineteen patients were lost for follow-up (11
deceased). Clinical treatment was associated with significant improvement of cognitive scores,
particularly on the Digit Symbol (p < 0.01) and Letter Cancellation Tests (p < 0.01). Digit Span,
Digit Symbol, Letter Cancellation and Trail Making scores of treated CHF patients and controls
were similar (p > 0.10).
Conclusions:  CHF is associated with deficits in attention and psychomotor speed. These deficits
improve with clinical treatment.
Introduction
Congestive heart failure (CHF) is a common complica-
tion of most diseases of the heart. Its prevalence increas-
es exponentially from age 60 years [1], such that CHF is
now one of the leading causes of hospitalisation, morbid-
ity and mortality in Western societies [2]. The findings of
several surveys indicate that physical, social, work, and
leisure activities are significantly impaired amongst CHF
subjects [3]. Psychological distress is also frequent, al-
though data on this important aspect of the quality of life
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of patients remain sparse and difficult to interpret. De-
pression rates, for example, seem to be high (up to 58%)
both in inpatient and outpatient settings [4,5]. Another
important, but neglected, aspect of the quality of life of
patients with CHF is cognitive functioning. Early reports
indicated that up to 80% of patients with severe CHF dis-
play deficits in memory and other cognitive abilities [6].
The consequences of these deficits are not clear, but it is
conceivable that patients with cognitive impairment
have even higher morbidity and mortality rates. For ex-
ample, Cline et al. [7] reported that 10 of their 22 patients
were unable to name the medication they were receiving
for the treatment of CHF, 11/22 could not state the doses,
and 14/22 failed to remember when to take their tablets.
All subjects were surveyed 30 days after receiving de-
tailed verbal and written information about their treat-
ment regimen. Failing to take the prescribed medication,
in such cases, may increase the frequency of clinical com-
plications associated with CHF.
A recent meta-analysis confirmed that cognitive impair-
ment, particularly attentional deficits, are prominent
amongst CHF patients [8]. In addition, it seems that peo-
ple with severe forms of CHF (functional class II/III)
have greater difficulty than mild cases (functional class I)
to perform tasks such as digit span and trail making [9].
These results indicate that the attentional deficits associ-
ated with CHF may become more pronounced with in-
creasing severity of illness, although it is unclear whether
clinical treatment can reverse these deficits. We de-
signed the present study to clarify this question.
Methods
Subjects
We approached a consecutive sample of 63 adults aged
60 years or over admitted to a cardiology emergency
service (Heart Institute of São Paulo, Brazil) with prima-
ry diagnosis of CHF according to Carlson's criteria of
heart failure [10]. All subjects were classified as function-
al class IV (New York Heart Association, 1979) at the
time of admission to hospital [11] and had left ventricular
ejection fraction lower than 45%. Thirteen subjects with
a positive medical history of stroke during the previous 6
months, current diagnosis of depressive episode (ICD-
10), myocardial infarction during the previous 12 weeks,
severe anaemia (Hb lower than 10), orthopaedic prob-
lems that interfered with the subjects' ability to walk, il-
literacy and severe visual impairment (unable to read
font size 20) were excluded from further assessment.
We also recruited a sample of 30 controls amongst the
patients attending a geriatric outpatient service at the
same hospital. All subjects were aged 60 years or over
and had a left ventricular ejection fraction greater than
65%. Subjects with positive medical history of stroke,
current diagnosis of depressive episode (ICD-10), myo-
cardial infarction during the previous 12 weeks, severe
anaemia (Hb lower than 10), orthopaedic problems that
interfered with the subjects' ability to walk, illiteracy and
severe visual impairment (unable to read font size 20)
were not included in the control group.
Baseline assessment
Cardiological assessment
Each study participant was examined by either a cardiol-
ogist or geriatrician. The clinical assessment was de-
signed to clarify the diagnosis of CHF [10] and the
functional capacity of patients [11]. The left ventricular
ejection fraction (EF) was calculated from data derived
from 2-dimensional echocardiography according to the
formula: EF = (final diastolic volume – final systolic vol-
ume) / final diastolic volume. The correlation between
the calculated EF and direct volumetric measures are
greater than 0.9 and the coefficient of variance of the
method ranges from 3 to 6% [12]. Finally, CHF subjects
were asked to perform the 6-minute walk test in a flat
surface – this is a sensitive test of functional capacity that
produces, as a score, the total distance covered in metres
[13].
Mental state examination and cognitive assessment
All participants were assessed with the Cambridge Ex-
amination for Mental Disorders of the Elderly (CAM-
DEX)[14]. The CAMDEX is a semi-structured interview
used to evaluate the present mental state of older adults,
as well as their past medical and family history. This in-
terview covers a range of signs and symptoms that pro-
vide clinically relevant information necessary for the
diagnosis of mental disorders according to ICD-10 and
DSM-III-R, including dementia and depression (which
was an exclusion criteria in the present study). The cog-
nitive component of the CAMDEX, known as the CAM-
COG, includes several tests designed to assess
orientation, language, memory, praxis, attention, ab-
stract thinking and calculation. Scores range from 0 to
107 and include the 19 Mini-Mental State Examination
(MMSE) items. Both the CAMCOG and MMSE produce
valid and reliable measures of general cognitive abilities
[15,16].
The cognitive performance of subjects was further evalu-
ated with four tasks that measure, directly or indirectly,
attentional skills and visuomotor abilities: Digit Span
(forwards component only), Digit Symbol Test, Letter
Cancellation Test, and Trail Making A and B. The Digit
Span is part of the Wechsler Adult Intelligence Scale-Re-
vised (WAIS-R) [17] and provides a measure of span and
immediate recall. The test consists of seven pairs of a
random sequence of 2, 3, 4, 5, 6, 7, and 8 digits that the
examiner reads aloud at the rate of one per second (audi-BMC Geriatrics 2001, 1:2 http://www.biomedcentral.com/1471-2318/1/2
tory attention). The span of the subject is the maximum
number of paired digits that they are able to recall cor-
rectly. The Digit Symbol Test is also a subtest of the
WAIS-R [17]. It consists of four rows containing, in all,
100 small blank squares, each paired with a randomly as-
signed number from one to nine. Above these rows is a
printed key that pairs each number with a different non-
sense symbol. Following a practice trial, the task is to fill
in the blank spaces with the symbol that is paired to the
number above the blank space as quickly as possible for
90 seconds. The score is the number of squares filled in
correctly. The Letter Cancellation Test consists of six 52-
character rows in which the two target characters are
randomly interspersed approximately 18 times in each
row, as depicted by Lezak [18]. Subjects are asked to
strike the target characters through as quickly as possible
until they finish all the rows. In the present study, the
score of participants was recorded as the number of cor-
rectly identified target characters in 100 seconds (which
has been shown to be the median time necessary to com-
plete the task). Finally, subjects were asked to complete
the Trail Making Test A and B [18]. In the part A of the
test, the subject is asked to connect consecutively num-
bered circles, whereas on part B they have to alternate
between consecutive numbers and letters. The final
mark for each part of the test is the number of seconds
that the subject takes to complete the task.
Single photon emission tomography (SPECT)
A convenience sub-sample of 6 patients with CHF who
consented and were considered to be clinically capable of
going through the procedures involved in a SPECT as-
sessment, were recruited with the aim of measuring
brain blood perfusion using 99mTc-HMPAO. Images
were recorded by a gamma-camara (double-head Sophy-
camara model) and processed by a NXT computer. The
minimum resolution of this method is 6.1 mm per pixel.
The tracer (28 mCi/4 ml) was inject into the blood
stream after the patient had been resting for 15 minutes
in an environment with low sensory stimulation (closed
eyes and ear plugs were used). Immediately after the in-
jection, subjects were asked to perform a mental task:
consecutively add 3 starting from 1. The SPECT images
were recorded 15 minutes after the injection (patient ly-
ing down with closed eyes). Subjects were scanned with-
in 48 hours of their admission to the hospital.
Post-treatment assessment
The clinical treatment of patients was tailored to suit
each patient's individual needs, and included diet re-
strictions (such as salt intake), as well as the use of diu-
retics, ACE inhibitors, cardiotonic medication (such as
digoxin) and anti-arrhythmic drugs. The endpoint of
clinical treatment was improvement of functional status
from class-IV to class-I or II over the subsequent 6
weeks. Subjects with CHF were asked to repeat the 6-
minute walk test and all participants to perform the fol-
lowing cognitive tests: Digit Span, Digit Symbol Test,
Letter Cancellation Test, and Trail Making Test A and B.
Single photon emission tomography (SPECT)
Six subjects were reassessed with SPECT using the same
procedure described for the baseline assessment.
Data analysis
The data were analysed using the statistical package
'STATA-release 6.0'. Contingency tables using Pearson's
chi-square were utilised for the analyses of categorical
variables. Fisher's Exact Test was calculated when the
expected number within 2 or more cells was 5 or less. Be-
tween group comparisons of continuous numerical vari-
ables (in practical terms) was performed using Student's
t-test. Ordinal numerical variables (for example, digit
span score) were compared using Mann-Whitney test.
Similarly, intra-group comparisons were performed with
the Wilcoxon test. Spearman correlation coefficient was
used to investigate the strength of the association be-
tween EF and CAMCOG scores. Ninety-five percent con-
fidence limits (CI) were estimated for means and odds
ratio.
Results
Baseline assessment
A total of 50 patients with CHF and 30 elderly controls
met the study inclusion and exclusion criteria. Their de-
mographic and clinical history is summarised in table 1.
The EF ranged from 21 to 45% for CHF patients and 66
to 81% for controls. Controls were significantly older
than patients with CHF (p < 0.001) and were more likely
complain or memory difficulties (p = 0.030). In contrast,
CHF subjects reported an increased frequency of cere-
brovascular disease (p = 0.041) and having ever regularly
smoked more than 20 cigarettes per day (p = 0.012) or
used alcohol (p = 0.001). Seven CHF patients reported
prior history of stroke, although none of the patients dis-
played neurological deficits or handicap at the time of as-
sessment (table 1).
CHF subjects had significantly lower CAMCOG and
MMSE scores even after the analyses were adjusted for
age (p < 0.001 for both). A total of 44.9% of CHF patients
and 10% of controls had CAMCOG total scores below 70
(Χ 2 = 10.5, p = 0.001). Similarly, 54.0% and 33.3% of pa-
tients and elderly controls had MMSE scores below 24
(Χ 2 = 3.2, p = 0.073). Table 2 summarises the cognitive
performance of CHF patients and controls. The results
show that the performance of patients was worse than
that of controls in all neuropsychological tests. Our re-
sults showed that there was a moderate correlation be-
tween EF and CAMCOG scores (Spearman rho = 0.40, pBMC Geriatrics 2001, 1:2 http://www.biomedcentral.com/1471-2318/1/2
= 0.001). There was also a significant correlation be-
tween EF and the scores of the Digit Span (Spearman rho
= 0.25, p = 0.026), Digit Symbol (Spearman rho = 0.45,
p < 0.001), Letter Cancellation (Spearman rho = 0.33, p
= 0.003), and Trail Making A (Spearman rho = -0.28, p
= 0.013) and B (Spearman rho = -0.34, p = 0.003).
Dropouts
Nineteen of the 50 patients with CHF included in the
study were not available for follow-up assessment after 6
weeks – 11/19 died and the other 8 were either critically
ill or withdrew consent to participate. We compared
baseline scores on clinical and cognitive assessments of
CHF subjects who dropped out with those who were
available at follow-up. Age, gender, prior history of myo-
Table 1: Demographic and clinical features of patients with CHF and elderly controls at baseline
CHF (n = 50) Controls (n = 30) Statistic p
Ejection fraction (mean) 37.0 74.2 t = 6.1 <0.001
CI 35.2 – 38.7 72.7 – 75.6
Age (mean years) 67.3 76.7 t = 6.1 <0.001
CI 65.6 – 69.0 73.8 – 79.5
Male gender (%) 76.0 66.7 Χ 2 = 0.8 0.365
Cerebrovascular symptoms (%) 16.0 13.3 Χ 2 = 0.1 0.476
Sleep difficulties (%) 16.0 36.7 Χ 2 = 4.4 0.035
Depression (%) 0 3.3 FET 0.375
Anxiety (%) 26.0 30.0 Χ 2 = 0.1 0.698
Memory complaints (%) 18.0 40.0 Χ 2 = 4.7 0.030
Paranoid symptoms (%) 0 3.3 FET 0.375
Prior myocardial infarction (%) 38.0 10.0 Χ 2 = 7.4 0.007
Hypertension (%) 64.0 50.0 Χ 2 = 1.5 0.218
Prior stroke (%) 14.0 0 FET 0.041
Current or previous smoking (%) 52.0 23.3 Χ 2 = 6.4 0.012
Regular use of alcohol (%) 28.0 0 FET 0.001
Prior psychiatric history (%) 0 0 - -
CI = 95% confidence interval of the mean. t = Statistical value of the Student's t-test. Χ 2 = Statistical value of Pearson's chi-square. FET = Fisher 
Exact Test.
Table 2: Cognitive scores of patients with CHF and elderly controls at baseline
CHF (n = 50) Controls (n = 30) Statistic p
MMSE (mean) 22.9 25.0 t = 2.6 0.011
CI 21.8 – 24.0 23.8 – 26.2
CAMCOG (mean) 71.8 82.0 t = 3.8 <0.001
CI 68.2 – 75.5 78.5 – 85.4
Digit Span (mean) 3.8 5.1 z = 3.1 0.002
CI 3.5 – 4.2 4.4 – 5.8
Digit Symbol (mean) 10.3 19.3 z = 4.1 <0.001
CI 8.2 – 12.5 14.8 – 23.8
Letter Cancellation (mean) 29.9 40.3 z = 3.1 0.002
CI 25.9 – 34.0 34.5 – 46.2
Trail Making A (mean) 36.2* 22.2 z=-1.8 0.077
CI 24.8 – 47.7 17.1 – 27.6
Trail Making B (mean) 72.9* 36.0 z=-2.8 0.004
CI 53.2 – 92.5 26.6 – 45.4
*Information on the Trail Making Test was missing for one patient with CHF. CI = 95% confidence interval of the mean. t = Statistical value of the 
Student's t-test. z = Standardised statistical value of the Mann-Whitney test.BMC Geriatrics 2001, 1:2 http://www.biomedcentral.com/1471-2318/1/2
cardial infarct or stroke, 6-minute walk test, EF, CAM-
COG, MMSE, Digit Span, and Trail Making A and B were
similar for both groups of patients. Interestingly, sub-
jects who dropped out had lower scores on the Digit
Symbol Test (mean = 7.4, IC = 5.1 – 9.6 vs mean = 12.2,
CI = 9.0 – 15.3; z = 2.1, p = 0.039) and Letter Cancella-
tion Test (mean = 25.2, IC = 20.9 – 29.4 vs mean = 32.8,
CI = 26.9 – 38.8; z = 1.8, p = 0.077).
Post-treatment assessment
Thirty-one CHF patients completed the 6 weeks of fol-
low-up. Clinical treatment was associated with signifi-
cant improvement of functional capacity as measured by
the 6-minute walk test (pretreatment = 312.4, CI = 269.7
– 355.0; post-treatment = 401.6, CI = 357.1 – 446.2; t =
-5.8, p < 0.001). Table 3 summarises the results on atten-
tional tasks before and after treatment – cognitive scores
improved for the Digit Symbol and Letter Cancellation
tests (all comparisons used Mann-Whitney test). These
results also show that controls and CHF patients after
treatment had similar scores in the attentional tasks
used in this study.
SPECT
A subsample of six patients with CHF were selected for
the assessment of brain blood flow before and after treat-
ment. Blood flow increased from 149.0 mCi (CI = 114.7 –
183.4) at baseline to 160.3 mCi (CI = 150.3 – 170.3) after
treatment (z = 1.2, p = 0.248). Figure 1 shows blood flow
changes for each individual patient.
Discussion
The results of the present study confirm that clinically
decompensated CHF is associated with attentional defi-
cits and generalised cognitive impairment. The clinical
significance of these findings is even more apparent
when one considers that the control group selected for
the study was 10 years older than the CHF group. In fact,
approximately half of the patients had CAMCOG and
MMSE scores below the cutoff points used to determine
the presence of cognitive impairment. Patients with CHF
had considerable difficulties performing even a relatively
simple attentional task such as the Digit Span.
Attentional deficits are expected amongst patients with a
severe and debilitating medical illness such as CHF. In
fact, subjects' performance in other cognitive tasks is
likely to be influenced by their presence, which may part-
ly explain the finding of generalised cognitive impair-
ment amongst patients. Gorkin et al. [9] showed that
subjects with more severe forms of CHF (functional class
II/III) have greater difficulty than controls (functional
class I) on digit span and trail making A tests. They also
found that performance on these tasks is associated with
decreased functional capacity, as measured by the 6-
minute walk test. Nonetheless, it is important to note
that the cognitive performance of patients may be influ-
enced by factors not directly related to the presence of
CHF, such as depression, anxiety, alcohol abuse, con-
comitant medical problems, and use of certain medica-
tions.
Table 3: Cognitive scores of patients with CHF before and after treatment and controls
CHFBT CHFAT Controls p p
(n = 31) (n = 31) (n = 30) CHFBT CHFAT
XX
CHFAT Controls
Digit Span (mean) 4.0 4.5 5.1 0.096 0.191
CI 3.5 – 4.6 3.9 – 5.1 4.4 – 5.8
Digit Symbol (mean) 12.2 15.8 19.3 <0.001 0.305
CI 9.0 – 15.3 12.3 – 19.2 14.8 – 23.8
Letter Cancellation (mean) 32.8 44.2 40.3 <0.001 0.624
CI 26.9 – 38.8 36.5 – 51.8 34.5 – 46.2
Trail Making A (mean) 35.3 27.9 22.2 0.313 0.691
CI 19.2 – 51.3 14.8 – 41.0 17.1 – 27.6
Trail Making B (mean) 78.5 58.1 36.0 0.080 0.133
CI 47.1 – 110.0 37.1 – 79.1 26.6 – 45.4
CI = 95% confidence interval of the mean. CHFBT = congestive heart failure patients before treatment. CHFAT = congestive heart failure patients 
after treatment. All comparisons between CHFBT and CHFAT performed with the Wilcoxon paired test. All comparisons between CHFAT and con-
trols performed with Mann-Whitney test. Note: only CHF patients who completed the two phases of the study were included in the analyses. Infor-
mation on the Trail Making Test was missing for one patient with CHF.BMC Geriatrics 2001, 1:2 http://www.biomedcentral.com/1471-2318/1/2
Our results also showed that the 6-week mortality rate of
patients with CHF recruited into the study was high
(22%) and was the main source of dropout from the
study. Interestingly, the most robust predictor of drop-
out was the baseline score on the Digit Symbol Test (the
result on the Letter Cancellation Test was marginally
non-significant). The clinical significance of this finding
requires further prospective evaluation.
The findings of the present study indicate that the clini-
cal treatment of CHF is associated with significant im-
provement in attentional scores. More importantly,
attentional scores of patients after treatment of CHF
were similar to those of elderly controls, which suggests
that these deficits may be, at least partly, reversible. Oth-
er studies had already shown that cognitive performance
improves with surgery [6], although, to our knowledge,
this is the first report showing that attentional deficits
can be reversed with clinical treatment. From a clinical
point of view, this finding is comparable to that of pa-
tients with other metabolic encephalopathies such as lu-
pus erythematosus [19]. It remains unclear at this point
whether such deficits interfere with the subject's ability
to provide informed consent – this issue requires further
investigation as patients with advanced heart failure may
be candidates for experimental therapies and high-risk
interventions such as cardiac transplantation.
The mechanisms that contribute to the development of
cognitive impairment among patients with CHF remain
unclear. Zucallà et al. [20] observed a linear relationship
between MMSE scores and left ventricular ejection frac-
tion rates for values lower than 40%. Similarly, Putzke et
al. [21] noted that Trail B, Digit Symbol Test and Stroop
scores were all significantly associated with cardiac out-
put. Cerebrovascular disease is another likely candidate,
as many patients with CHF have widespread cardiovas-
cular problems and are at increased risk for strokes. Data
derived from the Rotterdam study [22], for example, in-
dicate that white matter disease is associated with sub-
jective memory impairment and lower scores on tests of
cognitive function. Similarly, patients with strokes are
more likely to develop cognitive deficits and dementia.
Other cardiovascular problems such as low [23] and high
blood pressure [24], both frequent amongst patients
with CHF, are associated with cognitive impairment.
Cognitive impairment in CHF may also be due to the ab-
normal hormonal response that characterises the dis-
ease, although no direct evidence is currently available to
support this hypothesis. There is also the possibility that
the cognitive deficits in CHF are secondary to deficits in
blood supply to the brain. Our SPECT results indicated
the presence of a trend in that direction, with 5/6 sub-
jects showing a non-significant increase in blood flow to
the brain after clinical treatment. Alcohol abuse is anoth-
er factor that may contribute to the development cardio-
myopathy (and consequently lead to CHF) and cognitive
impairment. Hence, in clinical settings it is not uncom-
mon for patients with a positive history of alcohol abuse
or dependence to present with dementia and CHF at the
same time. The results of the present study indicate that
there was an excess of patients with CHF who made reg-
ular use of alcohol, although none of them showed signs
suggestive of the diagnosis of alcohol abuse or depend-
ence. Finally, the medications commonly used for the
treatment of CHF have an as yet unknown effect on cog-
nition and may, from a theoretical point of view, contrib-
ute to some of the deficits observed amongst patients.
Some limitations of the study should be considered be-
fore its results can be generalised. Only patients with
CHF were retested and their superior performance may
partly reflect learning rather than a direct effect of treat-
ment. However, the effect of learning on attentional
scores tends to be small [18] and is unlikely to have sig-
nificantly influenced our results. In addition, we must
acknowledge that the scores of subjects on tests such as
the Digit Symbol and Letter Cancellation may not neces-
sarily indicate the presence of attentional deficits, as per-
formance on these tests may be unrelated influenced by
psychomotor speed difficulties. There is also a possibility
that the improved scores were a direct result of the med-
ication used for the treatment of CHF, rather than
Figure 1
Changes in cerebral blood flow as measured by 99mTc-
HMPAO SPECT before and after clinical treatment of con-
gestive heart failure. Each line illustrates change in cerebral
blood flow from baseline to week 6 in an individual patient.BMC Geriatrics 2001, 1:2 http://www.biomedcentral.com/1471-2318/1/2
change in the clinical status of patients. At present, this
seems to be an unlikely explanation to our findings, al-
though we are unable to dismiss this hypothesis due to
lack of information on this subject. In addition, the as-
sessor was not blind to the clinical status of subjects,
which may have interfered with the scoring of tests. In
practice, however, this is improbable as most tests were
performed independently by study participants. Finally,
patients with CHF and elderly controls were not ade-
quately matched for age, although any performance bias
due to age should favour CHF patients – our findings
were in the opposite direction. However, this age differ-
ence may have influenced the comparisons between the
scores of patients after treatment and controls. Unfortu-
nately, we were unable to adjust the analysis for the ef-
fect of age, as patients and controls had significantly
different variances for the tests under consideration.
Conclusions
The results of the present study indicate that patients
with CHF functional class IV show a pattern of general-
ised cognitive impairment that includes attentional defi-
cits. We also showed that cognitive performance in this
population is correlated with left ventricular ejection
fraction, and that scores on attention tasks improve with
clinical treatment. Future studies should now attempt to
clarify the mechanisms that underlie cognitive function-
ing in CHF, as well as its long-term effects not only on at-
tention and psychomotor speed abilities but also in
general measures of cognitive functioning.
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